1.Alternative Name：TNFRSF7,Tp55；CD27 antigen; CD27 molecule; CD27; MGC20393; S152CD27L receptor; T cell activation antigen CD27; T cell activation antigen S152; T14; TNFRSF7; TNFRSF7T-cell activation antigen CD27; Tp55; Tumor necrosis factor receptor superfamily member 7; tumor necrosis factor receptor superfamily, member 7
2.Target：CD27
3.Source：Human CD27 was expressed from HEK293 with poly His at the C-terminal
4.Sequence：Thr21-Ile192
5.Protein structure:：P26842His
6.Molecular Characterization:The protein has a calculated MW of 21kDa.The reducing (R) heterodimer protein migrates as 35-60 kDa due to glycosylation
7.Purity:SDS-PAGE>90%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SPR

Recombinant Human CD70/ hFC Protein（Cat.No.B22045006）captured on Protein A chip , can bind Recombinant Human CD27/ His Protein（Cat.No.B22045002） with a KD constant of 4.95E-07M, determined in a SPR assay .

13.ELISA

When Recombinant Human CD27/ His Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD27 (Varlilumab) that produces 50% of the optimal binding response is approximately 40 ng/ml.

14.Note:For Research Use Only.